Original Article

You have full text access to this OnlineOpen article

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders†

  1. Jorge Cortes M.D.1,‡,§,*,
  2. Francis Giles M.D.1,
  3. Susan O'Brien M.D.1,
  4. Deborah Thomas M.D.1,
  5. Maher Albitar M.D.1,
  6. Mary Beth Rios M.D.1,
  7. Moshe Talpaz M.D.2,
  8. Guillermo Garcia-Manero M.D.1,
  9. Stefan Faderl M.D.1,
  10. Laurie Letvak M.D.3,
  11. August Salvado M.D.3,
  12. Hagop Kantarjian M.D.1

Article first published online: 19 MAY 2003

DOI: 10.1002/cncr.11416

Issue

Cancer

Cancer

Volume 97, Issue 11, pages 2760–2766, 1 June 2003

Additional Information

How to Cite

Cortes, J., Giles, F., O'Brien, S., Thomas, D., Albitar, M., Rios, M. B., Talpaz, M., Garcia-Manero, G., Faderl, S., Letvak, L., Salvado, A. and Kantarjian, H. (2003), Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer, 97: 2760–2766. doi: 10.1002/cncr.11416

Author Information

  1. 1

    Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Bioimmunotherapy, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas

  3. 3

    Novartis Pharmaceuticals Corporation, East Hanover, New Jersey

  1. ‡

    Dr. Cortes is a clinical research scholar for The Leukemia and Lymphoma Society, White Plains, New York.

  2. §

    Fax: (713) 794-4297

*Department of Leukemia, M. D. Anderson Cancer Center, 1515 Holcombe Blvd., P.O. Box 428, Houston, TX 77030

  1. †

    Dr. Armand Keating served as guest editor on this article.

Publication History

  1. Issue published online: 19 MAY 2003
  2. Article first published online: 19 MAY 2003
  3. Manuscript Accepted: 27 FEB 2003
  4. Manuscript Revised: 24 FEB 2003
  5. Manuscript Received: 13 DEC 2002

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (92K)

REFERENCES

  • 1
    Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2: 561–566.
  • 2
    Beran M, Cao X, Estrov Z, et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res. 1998; 4: 1661–1672.
  • 3
    Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346: 645–652.
  • 4
    Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002; 99: 3547–3553.
  • 5
    Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344: 1038–1042.
  • 6
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344: 1031–1037.
  • 7
    Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002; 99: 1928–1937.
  • 8
    Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002; 99: 3530–3539.
  • 9
    Ottmann OG, Druker BJ, Sawyers CL, et al. A Phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002; 100: 1965–1971.
  • 10
    Kantarjian HM, O'Brien S, Cortes JE, et al. Treatment of Philadelphia chromosome–positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002; 8: 2167–2176.
  • 11
    Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997; 90: 4947–4952.
  • 12
    Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000; 96: 925–932.
  • 13
    Bene MC, Bernier M, Casasnovas RO, et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). Blood. 1998; 92: 596–599.
  • 14
    Wells SJ, Bray RA, Stempora LL, Farhi DC. CD117/CD34 expression in leukemic blasts. Am J Clin Pathol. 1996; 106: 192–195.
  • 15
    Gersuk GM, Carmel R, Pattengale PK. Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders. Blood. 1989; 74: 2330–2334.
  • 16
    Rueda F, Pinol G, Marti F, Pujol-Moix N. Abnormal levels of platelet-specific proteins and mitogenic activity in myeloproliferative disease. Acta Haematol. 1991; 85: 12–15.
  • 17
    Cross NC, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia. 2002; 16: 1207–1212.
  • 18
    Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100: 2292–2302.
  • 19
    Cheson BD, Bennett JM, Kantarjian H, et al. Myelodysplastic syndromes standardized response criteria: further definition. Blood. 2001; 98: 1985.
  • 20
    Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990; 8: 813–819.
  • 21
    Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol. 2002; 20: 325–334.
  • 22
    Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347: 472–480.
  • 23
    Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279: 577–580.
  • 24
    Ma Y, Longley BJ, Wang X, Blount JL, Langley K, Caughey GH. Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. J Invest Dermatol. 1999; 112: 165–170.
  • 25
    Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002; 99: 1741–1744.
  • 26
    Ning ZQ, Li J, Arceci RJ. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood. 2001; 97: 3559–3567.
  • 27
    Ashman LK, Ferrao P, Cole SR, Cambareri AC. Effects of mutant c-kit in early myeloid cells. Leuk Lymphoma. 2000; 37: 233–243.
  • 28
    Broudy VC, Smith FO, Lin N, Zsebo KM, Egrie J, Bernstein ID. Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor. Blood. 1992; 80: 60–67.
  • 29
    Tajima F, Kawatani T, Ishiga K, Nanba E, Kawasaki H. Serum soluble c-kit receptor and expression of c-kit protein and mRNA in acute myeloid leukemia. Eur J Haematol. 1998; 60: 289–296.
    Direct Link:
  • 30
    Schwartz S, Heinecke A, Zimmermann M, et al. Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance. Leuk Lymphoma. 1999; 34: 85–94.
  • 31
    Reilly JT. Pathogenesis and management of idiopathic myelofibrosis. Baillieres Clin Haematol. 1998; 11: 751–767.
  • 32
    Tefferi A, Mesa RA, Gray LA, et al. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood. 2002; 99: 3854–3856.
  • 33
    Barosi G, Grossi A, Comotti B, Musto P, Gamba G, Marchetti M. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2001; 114: 78–83.
    Direct Link:
  • 34
    Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol. 2002; 117: 288–296.
    Direct Link:
  • 35
    Piccaluga PP, Visani G, Pileri SA, et al. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia. 2002; 16: 1609–1614.
  • 36
    Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994; 77: 307–316.
  • 37
    Ross TS, Bernard OA, Berger R, Gilliland DG. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood. 1998; 91: 4419–4426.
  • 38
    Schwaller J, Anastasiadou E, Cain D, et al. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood. 2001; 97: 3910–3918.
  • 39
    Magnusson MK, Meade KE, Brown KE, et al. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood. 2001; 98: 2518–2525.
  • 40
    Magnusson MK, Meade KE, Nakamura R, Barrett J, Dunbar CE. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood. 2002; 100: 1088–1091.
  • 41
    Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002; 347: 481–487.
  • 42
    Raza A, Lisak L, Dutt D, et al. Gleevec (imatinib mesylate) in 16 patients with chronic myelomonocytic leukemia (CMMoL) [abstract]. Blood. 2001; 98: 273b.
View Full Article (HTML) Get PDF (92K)